Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 8/20 | 0.61 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.55 |
| ▸ | AKR1C3 | P42330 | 4/20 | 0.53 |
| ▸ | PYGL | P06737 | 2/20 | 0.53 |
| ▸ | PYGM | P11217 | 1/20 | 0.53 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3602723 | 1.00 | GHSR (0.61) | GHSRHRH4AKR1C3PYGLPYGM | |
| SCHEMBL3613025 | 0.87 | HRH4 (0.56) | GHSRHRH4PYGLPYGMMLLT1 | |
| SCHEMBL3608941 | 0.87 | SMYD3 (0.65) | HRH4PYGLPYGM | |
| SCHEMBL3603886 | 0.87 | HRH4 (0.56) | GHSRHRH4PYGLPYGMMLLT1 | |
| SCHEMBL3608632 | 0.87 | MLLT1 (0.69) | GHSRHRH4PYGLPYGMMLLT1 | |
| SCHEMBL3608629 | 0.87 | MLLT1 (0.69) | GHSRHRH4PYGLPYGMMLLT1 | |
| SCHEMBL3603891 | 0.87 | HRH4 (0.56) | GHSRHRH4PYGLPYGMMLLT1 | |
| SCHEMBL3608944 | 0.87 | SMYD3 (0.65) | HRH4PYGLPYGM | |
| SCHEMBL3598547 | 0.85 | KDM4E (0.59) | HRH4AKR1C3PYGLPYGMMLLT1 | |
| SCHEMBL3598549 | 0.85 | KDM4E (0.59) | HRH4AKR1C3PYGLPYGMMLLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035862-A1 | NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-02-11 | — | — | US | claimed |
| US-20100035862-A1 | NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035862-A1 | NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF | IDO2, IDO1, INMT | GHSR 2639/4885HRH4 396/4885AKR1C3 2168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.